<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35108152</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China.</ArticleTitle>
        <Pagination>
          <StartPage>2021711</StartPage>
          <MedlinePgn>2021711</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2021711</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.2021711</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES">The aim of this study is to describe the reporting rate of adverse events following immunization (AEFI) with pentavalent vaccine: diphtheria-pertussis-tetanus-poliomyelitis-Haemophilus influenzae type b (DPT-IPV/Hib), and to determine whether the reporting rate of AEFI following DPT-IPV/Hib was higher than the average level of the other vaccines.</AbstractText>
          <AbstractText Label="METHODS">Review and describe the AEFI reported to national adverse event following immunization surveillance system (NAEFISS) in Zhejiang province from 2015 to 2020. Reporting rates of AEFI were calculated by age, city, severity of AEFI, categories of AEFI, and reaction categories. The data mining algorithm used in this study was reporting odds ratio (ROR). A value of ROR‑1.96SE &gt;1 (standard error [SE]) was considered as positive signal.</AbstractText>
          <AbstractText Label="RESULTS">NAEFISS received 5726 AEFI reports following DTP-IPV/Hib, with a reporting rate of 20.01/10000 doses. Of the reported AEFI, 202 were serious vaccine product-related reactions, including two cases of anaphylactic shock, five cases of Guillain Barre Syndrome (GBS) and two cases of acute disseminated encephalomyelitis. The reporting rate of fever/redness/induration was the highest among all the clinical diagnosis (14.97/10000 doses). The positive signals were obtained for allergic rash (ROR-1.96SE: 1.36), febrile convulsion (ROR-1.96SE: 1.32) and GBS (ROR-1.96SE: 1.16).</AbstractText>
          <AbstractText Label="CONCLUSION">The present findings bolstered that the DTP-IPV/Hib administered as the four-dose schedule was generally well tolerated in Chinese infants as we did not identify any new/unexpected safety concern from the NAEFISS during a six-year timespan.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Xuejiao</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Huakun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Linzhi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Fuxing</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yaping</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015721">Diphtheria-Tetanus-Pertussis Vaccine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018073">Haemophilus Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015721" MajorTopicYN="N">Diphtheria-Tetanus-Pertussis Vaccine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018073" MajorTopicYN="Y">Haemophilus Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019741" MajorTopicYN="Y">Haemophilus influenzae type b</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">AEFI (adverse events following immunization)</Keyword>
        <Keyword MajorTopicYN="Y">DPT-IPV/Hib(diphtheria-pertussis-tetanus-poliomyelitis-Hib combined vaccine)</Keyword>
        <Keyword MajorTopicYN="Y">safety</Keyword>
        <Keyword MajorTopicYN="Y">surveillance</Keyword>
        <Keyword MajorTopicYN="Y">vaccination</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>17</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35108152</ArticleId>
        <ArticleId IdType="pmc">PMC8986187</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2021.2021711</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hinman AR, Orenstein WA, Schuchat A.. 
Centers for disease, control prevention. Vaccine-preventable diseases, immunizations, and MMWR: 1961–2011. MMWR Surveill Summ. 2011;60:49–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21976166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Serres G, Gay NJ, Farrington CP. Epidemiology of transmissible diseases after elimination. Am J Epidemiol. 2000;151(11):1039–48. doi:10.1093/oxfordjournals.aje.a010145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.aje.a010145</ArticleId>
            <ArticleId IdType="pubmed">10873127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arístegui J, Usonis V, Coovadia H, Riedemann S, Win KM, Gatchalian S, Bock HL. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int J Infect Dis. 2003;7(2):143–51. doi:10.1016/S1201-9712(03)90011-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1201-9712(03)90011-7</ArticleId>
            <ArticleId IdType="pubmed">12839717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Wilson DP. Trends in notifiable infectious diseases in China: implications for surveillance and population health policy. PLoS One. 2012;7(2):e31076. doi:10.1371/journal.pone.0031076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0031076</ArticleId>
            <ArticleId IdType="pmc">PMC3281048</ArticleId>
            <ArticleId IdType="pubmed">22359565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R, Li CG, Li Y, Liu Y, Zhao H, Chen X, Kuriyakose S, Van Der Meeren O, Hardt K, Hezareh M, et al. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China. Vaccine. 2016;34(12):1436–43. doi:10.1016/j.vaccine.2016.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2016.02.010</ArticleId>
            <ArticleId IdType="pubmed">26873055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watt JP, Wolfson LJ, O’Brien KL, Henkle E, Deloria-Knoll M, McCall N, Lee E, Levine OS, Hajjeh R, Mulholland K, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet. 2009;374(9693):903–11. doi:10.1016/S0140-6736(09)61203-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(09)61203-4</ArticleId>
            <ArticleId IdType="pubmed">19748399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO Global Programme for Vaccines and Immunization . The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Weekly Epidemiol Record
1998;73:64–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9542461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skibinski DA, Baudner BC, Singh M, O’Hagan DT. Combination vaccines. J Glob Infect Dis. 2011;3(1):63–72. doi:10.4103/0974-777X.77298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0974-777X.77298</ArticleId>
            <ArticleId IdType="pmc">PMC3068581</ArticleId>
            <ArticleId IdType="pubmed">21572611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao PL, Lu CY, Hsieh YC, Bock HL, Huang LM. Taiwan Infanrix-069 Study G. Immunogenicity and reactogenicity of DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine for primary and booster vaccination of Taiwanese infants. J Formos Med Assoc. 2011;110:415–22. doi:10.1016/S0929-6646(11)60061-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0929-6646(11)60061-2</ArticleId>
            <ArticleId IdType="pubmed">21741011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asturias EJ, Contreras-Roldan IL, Ram M, Garcia-Melgar AJ, Morales-Oquendo V, Hartman K, Rauscher M, Moulton LH, Halsey NA. Post-authorization safety surveillance of a liquid pentavalent vaccine in Guatemalan children. Vaccine. 2013;31(49):5909–14. doi:10.1016/j.vaccine.2013.09.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2013.09.015</ArticleId>
            <ArticleId IdType="pubmed">24055354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anh DD, Van Der Meeren O, Karkada N, Assudani D, Yu TW, Han HH. Safety and reactogenicity of the combined diphtheria-tetanusacellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: an open-label, phase III study. Hum Vaccin Immunother. 2016;12:655–57. doi:10.1080/21645515.2015.1084451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2015.1084451</ArticleId>
            <ArticleId IdType="pmc">PMC4964705</ArticleId>
            <ArticleId IdType="pubmed">26337197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phua KB, Quak SH, Lim FS, Goh P, Teoh YL, Datta SK, Han HH, Bock HL. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b vaccine in a placebo-controlled rotavirus vaccine study. Ann Acad Med Singapore. 2008;37:546–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18695765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan X, Lv H, Chen F, Wang Y, Liang H, Shen L, Chen Y, Hu Y. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system. Hum Vaccin Immunother. 2021;17(10):3823–30. doi:10.1080/21645515.2021.1939621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2021.1939621</ArticleId>
            <ArticleId IdType="pmc">PMC8437471</ArticleId>
            <ArticleId IdType="pubmed">34170800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D, Wu W, Li K, Xu D, Ye J, Li L, Wang H. Surveillance of adverse events following immunization in China: past, present, and future. Vaccine. 2015;33(32):4041–46. doi:10.1016/j.vaccine.2015.04.060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2015.04.060</ArticleId>
            <ArticleId IdType="pubmed">25936727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rust J. Updating the international classification of diseases and related health problems, tenth revision (ICD-10). Health Info Manage J Health Inf Manage Assoc Aus. 2010;39(2):40. doi:10.1177/183335831003900207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/183335831003900207</ArticleId>
            <ArticleId IdType="pubmed">28683638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Li Q, Lin L, Chen E, Chen Y, Qi X. Surveillance for adverse events following immunization from 2008 To 2011 in Zhejiang Province, China. Clin Vaccine Immunol CVI. 2013;20:211–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3571262</ArticleId>
            <ArticleId IdType="pubmed">23239804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Chen Y. Evaluating childhood vaccination coverage of NIP vaccines: coverage survey versus Zhejiang Provincial immunization information system. Int J Environ Res Public Health. 2017;14:
758 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5551196</ArticleId>
            <ArticleId IdType="pubmed">28696387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S, Park K, Kim MS, Yang BR, Choi HJ, Park BJ. Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database. Psychiatry Res. 2017;256:237–42. doi:10.1016/j.psychres.2017.06.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psychres.2017.06.038</ArticleId>
            <ArticleId IdType="pubmed">28646789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt H-J, Von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):507–12. doi:10.1097/01.inf.0000222413.47344.23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.inf.0000222413.47344.23</ArticleId>
            <ArticleId IdType="pubmed">16732148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>David S, Bondt PE V-D, Van Der Maas NA. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands. Vaccine. 2008;26(46):5883–87. doi:10.1016/j.vaccine.2008.07.105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2008.07.105</ArticleId>
            <ArticleId IdType="pubmed">18775463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews N, Stowe J, Wise L, Miller E. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/Haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/Haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine. 2010;28(44):7215–20. doi:10.1016/j.vaccine.2010.08.062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2010.08.062</ArticleId>
            <ArticleId IdType="pubmed">20800702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li G, Zhang H, Zhou W, Ye Q, Li F, Wang H, Hou Q, Xu Y, Ma X, Tan Y, et al. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization. Vaccine. 2010;28(25):4215–23. doi:10.1016/j.vaccine.2010.03.061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2010.03.061</ArticleId>
            <ArticleId IdType="pubmed">20399240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White C, Halperin SA, Scheifele DW. Pediatric combined formulation DTaP-IPV/Hib vaccine. Expert Rev Vaccines. 2009;8(7):831–40. doi:10.1586/erv.09.59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/erv.09.59</ArticleId>
            <ArticleId IdType="pubmed">19538110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Black S, Greenberg DP. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Expert Rev Vaccines. 2005;4(6):793–805. doi:10.1586/14760584.4.6.793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14760584.4.6.793</ArticleId>
            <ArticleId IdType="pubmed">16372875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Data System Rev. 2009;3:Cd005530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19588375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomianovic D, Bauwens J, Heininger U, Bonhoeffer J. Global vaccine safety assessment: challenges and opportunities. Pediatr Infect Dis J. 2016;35(4):446–48. doi:10.1097/INF.0000000000000983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0000000000000983</ArticleId>
            <ArticleId IdType="pubmed">26555389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon D, Kim JH, Lee H, Shin JY. Updates on vaccine safety and post-licensure surveillance for adverse events following immunization in South Korea, 2005-2017. Yonsei Med J. 2020;61:623–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7329746</ArticleId>
            <ArticleId IdType="pubmed">32608206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira PMN, Lignani LK, Conceicao DAD, Farias P, Takey PRG, Maia MLS, Camacho L. Surveillance of adverse events following immunization in the late 2010s: an overview of the importance, tools, and challenges. Cad Saude Publica. 2020;36(Suppl 2):e00182019. doi:10.1590/0102-311x00182019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/0102-311x00182019</ArticleId>
            <ArticleId IdType="pubmed">32965327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nabavi M, Jandaghi J, Ghorbani R, Khaleghi Hashemian M, Shojaee H, Maherbonabi S, Mohammadzade F, Ghadamyari M, Bayat S, Faraji Z. The incidence of complications of vaccination in children and infants of Semnan, Iran. Koomesh. 2010;11:245–54.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharafi R, Mortazavi J, Heidarzadeh A. Comparison of complications of pentavalent and DTP vaccination in infants aged 2–6 months in Anzali, Iran. Iran J Neonatology IJN. 2016;7:1–6.</Citation>
        </Reference>
        <Reference>
          <Citation>Chhatwal J, Lalwani S, Vidor E. Immunogenicity and safety of a liquid Hexavalent vaccine in Indian infants. Indian Pediatr. 2017;54(1):15–20. doi:10.1007/s13312-017-0989-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13312-017-0989-2</ArticleId>
            <ArticleId IdType="pubmed">27889711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynolds DL, Vidor E. Fully liquid DTaP-IPV-Hib pediatric combination vaccine (Pediacel): a review of 18 years of clinical experience. Expert Rev Vaccines. 2014;13:943–68. doi:10.1586/14760584.2014.933674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14760584.2014.933674</ArticleId>
            <ArticleId IdType="pubmed">24985159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Chen CJ, Chavand P, Ortiz E. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. Int J Infect Dis. 2007;11(6):488–95. doi:10.1016/j.ijid.2007.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2007.01.006</ArticleId>
            <ArticleId IdType="pubmed">17349809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dagan R, Igbaria K, Piglansky L, Melamed R, Willems P, Grossi A, Kaufhold A. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatr Infect Dis J. 1997;16:1113–21. doi:10.1097/00006454-199712000-00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00006454-199712000-00004</ArticleId>
            <ArticleId IdType="pubmed">9427455</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35108152</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China.</ArticleTitle>
        <Pagination>
          <StartPage>2021711</StartPage>
          <MedlinePgn>2021711</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2021711</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.2021711</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES">The aim of this study is to describe the reporting rate of adverse events following immunization (AEFI) with pentavalent vaccine: diphtheria-pertussis-tetanus-poliomyelitis-Haemophilus influenzae type b (DPT-IPV/Hib), and to determine whether the reporting rate of AEFI following DPT-IPV/Hib was higher than the average level of the other vaccines.</AbstractText>
          <AbstractText Label="METHODS">Review and describe the AEFI reported to national adverse event following immunization surveillance system (NAEFISS) in Zhejiang province from 2015 to 2020. Reporting rates of AEFI were calculated by age, city, severity of AEFI, categories of AEFI, and reaction categories. The data mining algorithm used in this study was reporting odds ratio (ROR). A value of ROR‑1.96SE &gt;1 (standard error [SE]) was considered as positive signal.</AbstractText>
          <AbstractText Label="RESULTS">NAEFISS received 5726 AEFI reports following DTP-IPV/Hib, with a reporting rate of 20.01/10000 doses. Of the reported AEFI, 202 were serious vaccine product-related reactions, including two cases of anaphylactic shock, five cases of Guillain Barre Syndrome (GBS) and two cases of acute disseminated encephalomyelitis. The reporting rate of fever/redness/induration was the highest among all the clinical diagnosis (14.97/10000 doses). The positive signals were obtained for allergic rash (ROR-1.96SE: 1.36), febrile convulsion (ROR-1.96SE: 1.32) and GBS (ROR-1.96SE: 1.16).</AbstractText>
          <AbstractText Label="CONCLUSION">The present findings bolstered that the DTP-IPV/Hib administered as the four-dose schedule was generally well tolerated in Chinese infants as we did not identify any new/unexpected safety concern from the NAEFISS during a six-year timespan.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Xuejiao</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Huakun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Linzhi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Fuxing</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yaping</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015721">Diphtheria-Tetanus-Pertussis Vaccine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018073">Haemophilus Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015721" MajorTopicYN="N">Diphtheria-Tetanus-Pertussis Vaccine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018073" MajorTopicYN="Y">Haemophilus Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019741" MajorTopicYN="Y">Haemophilus influenzae type b</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">AEFI (adverse events following immunization)</Keyword>
        <Keyword MajorTopicYN="Y">DPT-IPV/Hib(diphtheria-pertussis-tetanus-poliomyelitis-Hib combined vaccine)</Keyword>
        <Keyword MajorTopicYN="Y">safety</Keyword>
        <Keyword MajorTopicYN="Y">surveillance</Keyword>
        <Keyword MajorTopicYN="Y">vaccination</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>17</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35108152</ArticleId>
        <ArticleId IdType="pmc">PMC8986187</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2021.2021711</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hinman AR, Orenstein WA, Schuchat A.. 
Centers for disease, control prevention. Vaccine-preventable diseases, immunizations, and MMWR: 1961–2011. MMWR Surveill Summ. 2011;60:49–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21976166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Serres G, Gay NJ, Farrington CP. Epidemiology of transmissible diseases after elimination. Am J Epidemiol. 2000;151(11):1039–48. doi:10.1093/oxfordjournals.aje.a010145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.aje.a010145</ArticleId>
            <ArticleId IdType="pubmed">10873127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arístegui J, Usonis V, Coovadia H, Riedemann S, Win KM, Gatchalian S, Bock HL. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int J Infect Dis. 2003;7(2):143–51. doi:10.1016/S1201-9712(03)90011-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1201-9712(03)90011-7</ArticleId>
            <ArticleId IdType="pubmed">12839717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Wilson DP. Trends in notifiable infectious diseases in China: implications for surveillance and population health policy. PLoS One. 2012;7(2):e31076. doi:10.1371/journal.pone.0031076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0031076</ArticleId>
            <ArticleId IdType="pmc">PMC3281048</ArticleId>
            <ArticleId IdType="pubmed">22359565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R, Li CG, Li Y, Liu Y, Zhao H, Chen X, Kuriyakose S, Van Der Meeren O, Hardt K, Hezareh M, et al. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China. Vaccine. 2016;34(12):1436–43. doi:10.1016/j.vaccine.2016.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2016.02.010</ArticleId>
            <ArticleId IdType="pubmed">26873055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watt JP, Wolfson LJ, O’Brien KL, Henkle E, Deloria-Knoll M, McCall N, Lee E, Levine OS, Hajjeh R, Mulholland K, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet. 2009;374(9693):903–11. doi:10.1016/S0140-6736(09)61203-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(09)61203-4</ArticleId>
            <ArticleId IdType="pubmed">19748399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO Global Programme for Vaccines and Immunization . The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Weekly Epidemiol Record
1998;73:64–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9542461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skibinski DA, Baudner BC, Singh M, O’Hagan DT. Combination vaccines. J Glob Infect Dis. 2011;3(1):63–72. doi:10.4103/0974-777X.77298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0974-777X.77298</ArticleId>
            <ArticleId IdType="pmc">PMC3068581</ArticleId>
            <ArticleId IdType="pubmed">21572611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao PL, Lu CY, Hsieh YC, Bock HL, Huang LM. Taiwan Infanrix-069 Study G. Immunogenicity and reactogenicity of DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine for primary and booster vaccination of Taiwanese infants. J Formos Med Assoc. 2011;110:415–22. doi:10.1016/S0929-6646(11)60061-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0929-6646(11)60061-2</ArticleId>
            <ArticleId IdType="pubmed">21741011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asturias EJ, Contreras-Roldan IL, Ram M, Garcia-Melgar AJ, Morales-Oquendo V, Hartman K, Rauscher M, Moulton LH, Halsey NA. Post-authorization safety surveillance of a liquid pentavalent vaccine in Guatemalan children. Vaccine. 2013;31(49):5909–14. doi:10.1016/j.vaccine.2013.09.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2013.09.015</ArticleId>
            <ArticleId IdType="pubmed">24055354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anh DD, Van Der Meeren O, Karkada N, Assudani D, Yu TW, Han HH. Safety and reactogenicity of the combined diphtheria-tetanusacellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: an open-label, phase III study. Hum Vaccin Immunother. 2016;12:655–57. doi:10.1080/21645515.2015.1084451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2015.1084451</ArticleId>
            <ArticleId IdType="pmc">PMC4964705</ArticleId>
            <ArticleId IdType="pubmed">26337197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phua KB, Quak SH, Lim FS, Goh P, Teoh YL, Datta SK, Han HH, Bock HL. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b vaccine in a placebo-controlled rotavirus vaccine study. Ann Acad Med Singapore. 2008;37:546–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18695765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan X, Lv H, Chen F, Wang Y, Liang H, Shen L, Chen Y, Hu Y. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system. Hum Vaccin Immunother. 2021;17(10):3823–30. doi:10.1080/21645515.2021.1939621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2021.1939621</ArticleId>
            <ArticleId IdType="pmc">PMC8437471</ArticleId>
            <ArticleId IdType="pubmed">34170800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D, Wu W, Li K, Xu D, Ye J, Li L, Wang H. Surveillance of adverse events following immunization in China: past, present, and future. Vaccine. 2015;33(32):4041–46. doi:10.1016/j.vaccine.2015.04.060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2015.04.060</ArticleId>
            <ArticleId IdType="pubmed">25936727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rust J. Updating the international classification of diseases and related health problems, tenth revision (ICD-10). Health Info Manage J Health Inf Manage Assoc Aus. 2010;39(2):40. doi:10.1177/183335831003900207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/183335831003900207</ArticleId>
            <ArticleId IdType="pubmed">28683638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Li Q, Lin L, Chen E, Chen Y, Qi X. Surveillance for adverse events following immunization from 2008 To 2011 in Zhejiang Province, China. Clin Vaccine Immunol CVI. 2013;20:211–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3571262</ArticleId>
            <ArticleId IdType="pubmed">23239804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Chen Y. Evaluating childhood vaccination coverage of NIP vaccines: coverage survey versus Zhejiang Provincial immunization information system. Int J Environ Res Public Health. 2017;14:
758 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5551196</ArticleId>
            <ArticleId IdType="pubmed">28696387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S, Park K, Kim MS, Yang BR, Choi HJ, Park BJ. Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database. Psychiatry Res. 2017;256:237–42. doi:10.1016/j.psychres.2017.06.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psychres.2017.06.038</ArticleId>
            <ArticleId IdType="pubmed">28646789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt H-J, Von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):507–12. doi:10.1097/01.inf.0000222413.47344.23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.inf.0000222413.47344.23</ArticleId>
            <ArticleId IdType="pubmed">16732148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>David S, Bondt PE V-D, Van Der Maas NA. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands. Vaccine. 2008;26(46):5883–87. doi:10.1016/j.vaccine.2008.07.105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2008.07.105</ArticleId>
            <ArticleId IdType="pubmed">18775463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews N, Stowe J, Wise L, Miller E. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/Haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/Haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine. 2010;28(44):7215–20. doi:10.1016/j.vaccine.2010.08.062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2010.08.062</ArticleId>
            <ArticleId IdType="pubmed">20800702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li G, Zhang H, Zhou W, Ye Q, Li F, Wang H, Hou Q, Xu Y, Ma X, Tan Y, et al. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization. Vaccine. 2010;28(25):4215–23. doi:10.1016/j.vaccine.2010.03.061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2010.03.061</ArticleId>
            <ArticleId IdType="pubmed">20399240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White C, Halperin SA, Scheifele DW. Pediatric combined formulation DTaP-IPV/Hib vaccine. Expert Rev Vaccines. 2009;8(7):831–40. doi:10.1586/erv.09.59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/erv.09.59</ArticleId>
            <ArticleId IdType="pubmed">19538110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Black S, Greenberg DP. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Expert Rev Vaccines. 2005;4(6):793–805. doi:10.1586/14760584.4.6.793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14760584.4.6.793</ArticleId>
            <ArticleId IdType="pubmed">16372875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Data System Rev. 2009;3:Cd005530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19588375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomianovic D, Bauwens J, Heininger U, Bonhoeffer J. Global vaccine safety assessment: challenges and opportunities. Pediatr Infect Dis J. 2016;35(4):446–48. doi:10.1097/INF.0000000000000983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0000000000000983</ArticleId>
            <ArticleId IdType="pubmed">26555389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon D, Kim JH, Lee H, Shin JY. Updates on vaccine safety and post-licensure surveillance for adverse events following immunization in South Korea, 2005-2017. Yonsei Med J. 2020;61:623–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7329746</ArticleId>
            <ArticleId IdType="pubmed">32608206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira PMN, Lignani LK, Conceicao DAD, Farias P, Takey PRG, Maia MLS, Camacho L. Surveillance of adverse events following immunization in the late 2010s: an overview of the importance, tools, and challenges. Cad Saude Publica. 2020;36(Suppl 2):e00182019. doi:10.1590/0102-311x00182019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/0102-311x00182019</ArticleId>
            <ArticleId IdType="pubmed">32965327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nabavi M, Jandaghi J, Ghorbani R, Khaleghi Hashemian M, Shojaee H, Maherbonabi S, Mohammadzade F, Ghadamyari M, Bayat S, Faraji Z. The incidence of complications of vaccination in children and infants of Semnan, Iran. Koomesh. 2010;11:245–54.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharafi R, Mortazavi J, Heidarzadeh A. Comparison of complications of pentavalent and DTP vaccination in infants aged 2–6 months in Anzali, Iran. Iran J Neonatology IJN. 2016;7:1–6.</Citation>
        </Reference>
        <Reference>
          <Citation>Chhatwal J, Lalwani S, Vidor E. Immunogenicity and safety of a liquid Hexavalent vaccine in Indian infants. Indian Pediatr. 2017;54(1):15–20. doi:10.1007/s13312-017-0989-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13312-017-0989-2</ArticleId>
            <ArticleId IdType="pubmed">27889711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynolds DL, Vidor E. Fully liquid DTaP-IPV-Hib pediatric combination vaccine (Pediacel): a review of 18 years of clinical experience. Expert Rev Vaccines. 2014;13:943–68. doi:10.1586/14760584.2014.933674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14760584.2014.933674</ArticleId>
            <ArticleId IdType="pubmed">24985159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Chen CJ, Chavand P, Ortiz E. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. Int J Infect Dis. 2007;11(6):488–95. doi:10.1016/j.ijid.2007.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2007.01.006</ArticleId>
            <ArticleId IdType="pubmed">17349809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dagan R, Igbaria K, Piglansky L, Melamed R, Willems P, Grossi A, Kaufhold A. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatr Infect Dis J. 1997;16:1113–21. doi:10.1097/00006454-199712000-00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00006454-199712000-00004</ArticleId>
            <ArticleId IdType="pubmed">9427455</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
